Nemera presents its pen injector’s offer to reach customers and patients’ needs

Nemera presents its pen injector’s offer to reach customers and patients’ needs

From our platforms to your pen injector


Parenteral administration has several significant advantages such as better bioavailability, faster onset of effect, more predictable pharmacokinetic and pharmacodynamic profiles and avoiding the first-pass effect. For self-injected drugs, the user interface plays an important role in the catalogue of factors that influence patient compliance, while reducing the complexity of the drug administration procedure has been highlighted as particularly important.
In order to increase patients’ compliance and adherence as well as to accommodate pharmaceuticals’ needs, developing a device platform needs to be strategically defined as we must ensure that it is designed for a maximum possible range of potential therapeutic areas and patient populations.
Thanks to the Insight Product Development and Copernicus acquisition in 2019 and 2020 respectively, Nemera continues to reinforce its focus and purpose of always putting the patient at the center of everything they do, by becoming the partner of choice for the design, development, and production of devices, including pen injectors.
Today, Nemera offers four product platforms for pen development and manufacturing. These include reusable and disposable devices, namely PENDURA AD®, PENONE®, PENVARIO®, and PENHV®, which are designed for various therapies to meet key users’ needs. Check out the full article where Nemera discuss the development of the company’s pen injector platforms, and how they are tailored to meet the customers’ and patients’ needs.


To download the full article: Application note: From our platforms to your pen injector (

About the author:

Radosław Romańczuk, MD, Pen Platform Business Development Director, has over 20 years of experience in the life sciences industry. He is the author of the concept of a series of pen injectors, produced by Copernicus, which was acquired by Nemera in 2020.
The development and usability of medical technologies is perceived by Dr Radoslaw in three dimensions, representing his versatile experience – the perspective of a medical doctor, the perspective of the person managing marketing and business development in a biotechnological company, and the perspective of a person in charge of development of pen injectors franchise within a patient-centric device manufacturing organisation.

Séverine Duband is Marketing Director for drug delivery Devices at Nemera, steering overall category strategy, product portfolio and innovation development for five key delivery routes. She has been leading the parenteral segment at Nemera since 2018, focusing on proprietary products such as safety systems, pen injectors and on-body injectors. Ms Duband graduated from Emlyon Business School (Lyon, France) in 2004, and joined Nemera’s Global Marketing team in 2018 as a Global Category Manager, focusing on the parenteral segment.

Audrey Chandra is the Category Project Manager at Nemera. She joined Nemera in 2019. Ms Chandra graduated from the Faculty of Medicine, Atma Jaya University (Jakarta, Indonesia) and pursued her master’s degree in strategy and business development at Toulouse School of Management (France). With her dual competencies, she is in charge of providing strategic support for various targeted marketing projects. Additionally,
Ms Chandra actively works on diverse content management along with communication activities co-ordination.

About Nemera

As a world-leading drug delivery device solutions provider, our purpose of putting patients first enables us to design and manufacture devices that maximize treatment efficacy. We are a holistic partner and help our customers succeed in the sprint to market of their combination products. From early device strategy to state-of-the-art manufacturing, we’re committed to the highest quality standards. Agile and open-minded, we work with our customers as colleagues. Together, we go the extra mile to fulfill our mission.
For more information, visit